AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

Core Insights - The company believes the results indicate the drug's potential to significantly change the treatment landscape for hypophosphatasia [1] - The company intends to submit the data to regulators at the earliest opportunity [1]